BioVentures Institute Sp. z o.o. received funding from the European Union (EU)

BioVentures Institute Sp. z o.o. received funding from the European Union (EU) via the National Centre for Research and Development (NCBiR) in cooperation with the Molecular Biotechnology Department, Faculty of Chemistry and Molecular Biology Department, Faculty of Biology, University of Gdansk, in the amount of 3 209 930 PLN (POIG.01.04.00-22-140/12) for the development of novel, recombinant DNA-based technology for generating artificial, hyper immunogenic antigens/vaccines, entitled: „A new technology of producing preventive and therapeutic vaccines for multiple stimulation of the human immune system”. The technology is universal, thus can be applied to most antigens, however, our first targets are HIV, HCV and HBV viruses.

The scientific cooperation

The scientific cooperation between BioVentures Institute Sp. z o.o., Thermo Fisher Scientific and Department of Environmental Molecular Biotechnology, Institute for Environmental and Human Health Protection, Faculty of Chemistry, University of Gdansk, has generated new molecular tools for genetic engineering. Selected results have been published in an influential scientific journal (“Related bifunctional restriction endonuclease-methyltransferase triplets: TspDTI, Tth111II/TthHB27I and TsoI with distinct specificities.” BMC Molecular Biology, 2012, 13:13).

Research affiliation

Research affiliation between BioVentures Institute Sp. z o.o. and Department of Hepatology and Acquired Immunodeficiency, Medical University of Warsaw (Poland) concerning novel recombinant antiviral vaccines generation strategy has been established. The cooperation has already resulted in shared grant applications and in obtaining positive experimental results in the construction of specialized DNA vectors and fusion proteins, designed for the field of applied medicine.